Adjuvant Capital Management, LLC, 10% Owner at AN2 Therapeutics, Inc. (ANTX), sold 1,810 shares at $16.15 ($29K) on 2023-11-14, disclosed to the SEC on 2023-11-16.
Scheduled sale ($29k) by 10% Owner under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $16.15 | 288 | $5K | 15.9% |
| 2 | $16.15 | 1,522 | $25K | 84.1% |
| Total | $16.15 avg | 1,810 | $29K | 100% |